Tamura Yuki, Sato Ken, Naganuma Atsushi, Murakami Tatsuma, Honda Kaho, Saito Shuichi, Hirato Junko, Ogawa Akira, Ikota Hayato, Kakizaki Satoru, Uraoka Toshio
Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center.
Department of Healthcare Informatics, Takasaki University of Health and Welfare.
Nihon Shokakibyo Gakkai Zasshi. 2024;121(8):695-706. doi: 10.11405/nisshoshi.121.695.
The severe acute respiratory syndrome coronavirus 2 vaccine has contributed to infection control and the prevention of complications due to coronavirus disease 2019 (COVID-19). Conversely, the COVID-19 vaccine has been associated with adverse effects due to liver injury caused by autoimmunity or drugs. To date, Japanese journals have only published five reports of autoimmune liver damage associated with the COVID-19 vaccination. Although the pathogenic mechanism has not yet been fully elucidated, corticosteroids or azathioprine have shown effectiveness in certain patients. However, there have been cases of liver injury resulting in deaths. Here, we encountered three patients who developed autoimmune hepatitis (AIH) within 10 days following vaccination. All three patients were treated with prednisolone (PSL) and achieved remission. However, the serum alanine aminotransferase levels in all cases were observed to either increase or cease to improve during the therapeutic course before PSL administration. It is therefore imperative to closely monitor liver injury after the COVID-19 vaccination. In cases where AIH is suspected and a recurrence of liver dysfunction occurs, PSL may be administered. Future considerations should not only encompass the underlying mechanism by which autoimmunity contributes to the development of liver injury following COVID-19 vaccination but also the optimal treatment period for PSL and the long-term prognosis of AIH after COVID-19 vaccination.
严重急性呼吸综合征冠状病毒2疫苗有助于控制感染和预防2019冠状病毒病(COVID-19)引起的并发症。相反,COVID-19疫苗与自身免疫或药物引起的肝损伤相关的不良反应有关。迄今为止,日本期刊仅发表了五篇与COVID-19疫苗接种相关的自身免疫性肝损伤报告。尽管致病机制尚未完全阐明,但皮质类固醇或硫唑嘌呤在某些患者中已显示出疗效。然而,已有肝损伤导致死亡的病例。在此,我们遇到了三名在接种疫苗后10天内发生自身免疫性肝炎(AIH)的患者。所有三名患者均接受泼尼松龙(PSL)治疗并实现缓解。然而,在所有病例中,血清丙氨酸转氨酶水平在PSL给药前的治疗过程中均出现升高或不再改善的情况。因此,在COVID-19疫苗接种后密切监测肝损伤至关重要。在怀疑AIH且出现肝功能障碍复发的情况下,可给予PSL。未来的考虑不仅应包括自身免疫导致COVID-19疫苗接种后肝损伤发生的潜在机制,还应包括PSL的最佳治疗期以及COVID-19疫苗接种后AIH的长期预后。